Literature DB >> 23734036

Risk of acute kidney injury associated with the use of fluoroquinolones.

Steven T Bird1, Mahyar Etminan, James M Brophy, Abraham G Hartzema, Joseph A C Delaney.   

Abstract

BACKGROUND: Case reports indicate that the use of fluoroquinolones may lead to acute kidney injury. We studied the association between the use of oral fluoroquinolones and acute kidney injury, and we examined interaction with renin-angiotensin-system blockers.
METHODS: We formed a nested cohort of men aged 40-85 enrolled in the United States IMS LifeLink Health Plan Claims Database between 2001 and 2011. We defined cases as men admitted to hospital for acute kidney injury, and controls were admitted to hospital with a different presenting diagnosis. Using risk-set sampling, we matched 10 controls to each case based on hospital admission, calendar time (within 6 wk), cohort entrance (within 6 wk) and age (within 5 yr). We used conditional logistic regression to assess the rate ratio (RR) for acute kidney injury with current, recent and past use of fluoroquinolones, adjusted by potential confounding variables. We repeated this analysis with amoxicillin and azithromycin as controls. We used a case-time-control design for our secondary analysis.
RESULTS: We identified 1292 cases and 12 651 matched controls. Current fluoroquinolone use had a 2.18-fold (95% confidence interval [CI] 1.74-2.73) higher adjusted RR of acute kidney injury compared with no use. There was no association between acute kidney injury and recent (adjusted RR 0.87, 95% CI 0.66-1.16) or past (RR 0.86, 95% CI 0.66-1.12) use. The absolute increase in acute kidney injury was 6.5 events per 10 000 person-years. We observed 1 additional case per 1529 patients given fluoroquinolones or per 3287 prescriptions dispensed. The dual use of fluoroquinolones and renin-angiotensin-system blockers had an RR of 4.46 (95% CI 2.84-6.99) for acute kidney injury. Our case-time-control analysis confirmed an increased risk of acute kidney injury with fluoroquinolone use (RR 2.16, 95% CI 1.52-3.18). The use of amoxicillin or azithromycin was not associated with acute kidney injury.
INTERPRETATION: We found a small, but significant, increased risk of acute kidney injury among men with the use of oral fluoroquinolones, as well as a significant interaction between the concomitant use of fluoroquinolones and renin-angiotensin-system blockers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23734036      PMCID: PMC3708027          DOI: 10.1503/cmaj.121730

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  35 in total

1.  Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation.

Authors:  N Chopra; P L Fine; B Price; I Atlas
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

2.  Ciprofloxacin crystal nephropathy--a 'new' cause of acute renal failure.

Authors:  Martin Sedlacek; Arief A Suriawinata; Anton Schoolwerth; Brian D Remillard
Journal:  Nephrol Dial Transplant       Date:  2006-04-12       Impact factor: 5.992

3.  Oral contraceptives and the risk of gallbladder disease: a comparative safety study.

Authors:  Mahyar Etminan; Joseph A C Delaney; Brian Bressler; James M Brophy
Journal:  CMAJ       Date:  2011-04-18       Impact factor: 8.262

4.  Crystalluria and ciprofloxacin, influence of urinary pH and hydration.

Authors:  S B Thorsteinsson; T Bergan; S Oddsdottir; R Rohwedder; R Holm
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

Review 5.  Ciprofloxacin overdose: acute renal failure with prominent apoptotic changes.

Authors:  V R Dharnidharka; K Nadeau; C L Cannon; H W Harris; S Rosen
Journal:  Am J Kidney Dis       Date:  1998-04       Impact factor: 8.860

6.  Fluoroquinolone prescribing in the United States: 1995 to 2002.

Authors:  Jeffrey A Linder; Elbert S Huang; Michael A Steinman; Ralph Gonzales; Randall S Stafford
Journal:  Am J Med       Date:  2005-03       Impact factor: 4.965

7.  Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey.

Authors:  Orfeas Liangos; Ron Wald; John W O'Bell; Lorilyn Price; Brian J Pereira; Bertrand L Jaber
Journal:  Clin J Am Soc Nephrol       Date:  2005-10-26       Impact factor: 8.237

8.  Ciprofloxacin-induced renal dysfunction in patients with mycobacterial lung infections.

Authors:  W W Yew; C H Chau; P C Wong; H Y Choi
Journal:  Tuber Lung Dis       Date:  1995-04

9.  The association between drospirenone and hyperkalemia: a comparative-safety study.

Authors:  Steven T Bird; Salvatore R Pepe; Mahyar Etminan; Xinyue Liu; James M Brophy; Joseph Ac Delaney
Journal:  BMC Clin Pharmacol       Date:  2011-12-30

10.  ICD-10 coding algorithms for defining comorbidities of acute myocardial infarction.

Authors:  Lawrence So; Dewey Evans; Hude Quan
Journal:  BMC Health Serv Res       Date:  2006-12-15       Impact factor: 2.655

View more
  16 in total

1.  Dr Ben Franklin and an unusual modern-day cure for recurrent pleuritis.

Authors:  Mikaela I Poling; Craig R Dufresne; Robert L Chamberlain
Journal:  Br J Gen Pract       Date:  2017-01       Impact factor: 5.386

Review 2.  Communication and ciprofloxacin-associated acute kidney injury.

Authors:  Krishna Tirumala-Echampati; Darren M Roberts
Journal:  Aust Prescr       Date:  2018-08-01

Review 3.  Acute kidney injury-epidemiology, outcomes and economics.

Authors:  Oleksa Rewa; Sean M Bagshaw
Journal:  Nat Rev Nephrol       Date:  2014-01-21       Impact factor: 28.314

4.  Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Authors:  Taylor M Patek; Chengwen Teng; Kaitlin E Kennedy; Carlos A Alvarez; Christopher R Frei
Journal:  Drug Saf       Date:  2020-01       Impact factor: 5.606

5.  Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.

Authors:  Beatrice Alexandra Golomb; Hayley Jean Koslik; Alan J Redd
Journal:  BMJ Case Rep       Date:  2015-10-05

6.  Risk Factors Associated With Nephrotoxicity During Outpatient Intravenous Vancomycin Administration.

Authors:  Karen M Krueger; Lisa LaCloche; Amy Buros Stein; Ryan Kates; Milena Murray; Michael P Angarone
Journal:  J Pharm Technol       Date:  2021-11-18

7.  Concise Review: Current and Emerging Biomarkers of Nephrotoxicity.

Authors:  Elijah J Weber; Jonathan Himmelfarb; Edward J Kelly
Journal:  Curr Opin Toxicol       Date:  2017-04-12

8.  Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells.

Authors:  Sujan Badal; Yeng F Her; L James Maher
Journal:  J Biol Chem       Date:  2015-07-23       Impact factor: 5.157

9.  Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology.

Authors:  Steven T Bird; Joseph A C Delaney; James M Brophy; Mahyar Etminan; Sean C Skeldon; Abraham G Hartzema
Journal:  BMJ       Date:  2013-11-05

Review 10.  The growth of acute kidney injury: a rising tide or just closer attention to detail?

Authors:  Edward D Siew; Andrew Davenport
Journal:  Kidney Int       Date:  2014-09-17       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.